Administration of Intranasal Midazolam for Anxiety in Palliative Care

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2025

Conditions
AnxietyAcute AnxietyPalliative Care
Interventions
DRUG

Placebo Nasal Spray 0 mg/spray

"A unit-dose nasal spray will be used for the intervention.~1 spray (= 0.1 μl = 0 mg midazolam/spray) in each nostril, i.e., no active compound"

DRUG

Midazolam Nasal Spray 0.45 mg/spray

"A unit-dose nasal spray will be used for the intervention.~1 spray (= 0.1 μl = 0.45 mg midazolam/spray) in each nostril, i.e., total dose of midazolam 0.9 mg"

DRUG

Midazolam Nasal Spray 0.9 mg/spray

"A unit-dose nasal spray will be used for the intervention.~1 spray (= 0.1 μl = 0.9 mg midazolam/spray) in each nostril, i.e., total dose of midazolam 1.8 mg"

Trial Locations (5)

3010

NOT_YET_RECRUITING

Inselspital, Universitätsspital Bern, Bern

4052

RECRUITING

Palliativzentrum Bethesda Spital, Basel

8037

RECRUITING

Zentrum für Palliative Care, Stadtspital Zürich, Zurich

8091

RECRUITING

Kompetenzzentrum Palliative Care, Universitätsspital Zürich, Zurich

Unknown

RECRUITING

Universitäres Zentrum für Palliative Care (UZP), Bern

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER